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Summary
Merozoites of malaria parasites invade red blood
cells (RBCs), where they multiply by schizogony,
undergoing development through ring, trophozoite
and schizont stages that are responsible for
malaria pathogenesis. Here, we report that a
protein kinase-mediated signalling pathway involv-
ing host RBC PAK1 and MEK1, which do not have
orthologues in the Plasmodium kinome, is selec-
tively stimulated in Plasmodium falciparum-
infected (versus uninfected) RBCs, as determined
by the use of phospho-speciﬁc antibodies directed
against the activated forms of these enzymes.
Pharmacological interference with host MEK and
PAK function using highly speciﬁc allosteric
inhibitors in their known cellular IC50 ranges
results in parasite death. Furthermore, MEK inhibi-
tors have parasiticidal effects in vitro on hepato-
cyte and erythrocyte stages of the rodent malaria
parasite Plasmodium berghei, indicating conserva-
tion of this subversive strategy in malaria para-
sites. These ﬁndings have profound implications
for the development of novel strategies for anti-
malarial chemotherapy.cmi_1582 836..845
Introduction
Many intracellular pathogens, including unicellular
eukaryotic parasites, tailor their immediate environment to
their speciﬁc needs by affecting the properties of their
host cell (Haldar and Mohandas, 2007). Sporozoites of
malaria parasites ensure survival of their host hepatocyte
by preventing apoptosis and inﬂammation, through inter-
ference with host cell NF-kB and HGF pathways (Heus-
sler et al., 2006; Singh et al., 2007). Additional host
hepatocyte signalling protein kinases have been impli-
cated in Plasmodium liver-stage development (Prudencio
et al., 2008). Plasmodium relies on host heterotrimeric
G-proteins for the establishment of red blood cell (RBC)
infection (Harrison et al., 2003), suggesting the existence
of an interface between the parasite and host cell signal-
ling elements in blood stages as well. Even though RBCs
have no need for signalling pathways regulating gene
expression or cell proliferation, signalling elements includ-
ing MAPK (mitogen-activated protein kinase) modules are
nevertheless maintained (Ringrose et al., 2008), with pro-
posed functions in the regulation of ion transport (Sartori
et al., 1999) or membrane mechanical properties (Manno
et al., 2005). At the core of the MAPK pathways lies a
three-component module comprising the MAPK itself
(also called ERK, for extracellularly regulated kinase), its
activator the MAPKK (MEK, for MAPK/ERK kinase) and a
third, yet more upstream kinase, the MAPKKK or MEKK
(Raman et al., 2007). MEKK-independent MEK activation,
notably through the p21-activated protein kinase PAK,
has also been characterized (Slack-Davis et al., 2003;
Park et al., 2007). The Plasmodium kinome encodes two
divergent MAPKs (Dorin-Semblat et al., 2007), but clear
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cellular microbiologyorthologues of mammalian MEK1/2 and PAK have not
been identiﬁed in the parasite (Ward et al., 2004; Dorin
et al., 2005). Here we show that a host erythrocyte sig-
nalling pathway involving MEK1 and PAK1 is stimulated
by Plasmodium falciparum infection, and that pharmaco-
logical interference with this pathway using highly speciﬁc
allosteric inhibitors of human PAK and MEK enzymes
causes a block in parasite proliferation in both liver and
blood stages of mammalian host infection.
Results and discussion
Pharmacological evidence that host MEK activity is
required for parasite survival
In the course of our investigations on Plasmodium MAPK
pathways, we found that the highly selective MEK1/2
inhibitor U0126 inhibited P. falciparum proliferation, with
an IC50 value of 3 mM (Fig. 1A; see Fig. S1A for IC50
determination data) comparable to the 2 mMI C 50 value of
the compound in a mammalian T cell proliferation assay
(DeSilva et al., 1998). This is surprising, in view of the
absence of typical MEK homologues in the Plasmodium
kinome (Ward et al., 2004). Furthermore, the structurally
distinct allosteric MEK inhibitors PD98059 and PD184352
(also known as CI-1040) also had parasiticidal activity,
with IC50 values of 30 and 7 mM respectively (Fig. S1A).
The former value (for PD98059) is within the range of
known IC50 in various cell systems; the latter (for
PD184352) is similar to, but somewhat higher than, those
observed in mammalian cell assays: for example,
PD184352 causes cell cycle arrest of ﬁbroblasts with an
IC50 of ~1 mM (Squires et al., 2002). Treatment of synchro-
nized parasite populations with U0126 and PD184352
showed that both inhibitors block trophozoite develop-
ment (Fig. 1B), and that DNA synthesis is impaired in
parasites from treated cultures (Fig. 1C). In contrast,
when the inhibitors were added to synchronized cultures
of mature schizonts, we observed that egress, invasion
and establishment of the ring stage were unaffected, as
indicated by similar parasitaemia in the newly infected
erythrocytes in all samples (Fig. S2).
MEK inhibitors also have parasiticidal activity against
the rodent malaria parasite Plasmodium berghei, which
belongs to a distinct subgroup of the Plasmodium genus:
the sensitivity of P. berghei to PD184352 has a similar
level (IC50 = 8.3 mM, Fig. S3) and stage speciﬁcity (block
of trophozoite maturation, not shown) as that of P. falci-
parum (IC50 ~7 mM). Using a transgenic parasite line
expressing RFP (Graewe et al., 2009), we also demon-
strated an effect of 25 mM U0126 on the development of
P. berghei hepatocytic schizonts in HepG2 cells: intracel-
lular parasites within treated cells were signiﬁcantly
smaller than those in untreated cultures (Fig. 2A and B),
demonstrating that U0126 treatment clearly impairs para-
site growth and development of liver-stage parasites.
Interestingly, in the host kinome-wide siRNA knock-down
experiment reported by Prudencio et al. (2008) (see
Table S1 of this article), both a PAK isoform (see below)
and a MEK-interacting protein were identiﬁed as having a
detectable effect on liver infection.
Most protein kinase inhibitors target the ATP-binding
pocket and therefore tend to be poorly selective (Davis,
2000; Bain et al., 2007). In contrast, the allosteric MEK
inhibitors used in these experiments bind to a MEK-
speciﬁc pocket that is distinct from the ATP-binding
pocket, and freeze the enzyme in the inactive conforma-
tion (Ohren et al., 2004). This class of inhibitors thus dis-
plays exquisite selectivity against MEK1 and MEK2, with
lower activity against MEK5 as well (Bain et al., 2007).
Since the parasite’s kinome does not include orthologues
of these enzymes, this strongly suggests that in our
experiments their target is a human MEK rather than a
parasite-encoded protein. Mass spectrometry analysis of
an immunoprecipitate obtained with anti-human MEK1
antibodies from an uninfected human RBC extract
(Fig. 3A) identiﬁed 24 unique MEK1 peptides with a cov-
erage of 61% (Fig. 3B and C; see Fig. S4 for a list of
peptides), validating a previous mention (Roux-Dalvai
et al., 2008) of the presence of this enzyme in uninfected
erythrocytes.
Phosphorylation of MEK1 in infected erythrocytes
To detect a possible effect of infection on host MEK acti-
vation, we used the KPSS7.0 panel of antibodies from
Kinexus Corporation (Vancouver, Canada), which con-
tains a number of phospho-speciﬁc antibodies recogniz-
ing a panel of signalling molecules and covering several
phosphorylation sites on MEK1 and MEK2. Extracts from
uRBCs and iRBCs, normalized for cell number, were sub-
jected to Western blot analysis using the KSSP7.0 panel.
Strikingly, a very strong signal was obtained with the anti-
body against p[Ser-297] of human MEK1 only in the iRBC
sample (Fig. 4A; see Fig. S5 for the original Western blot
from Kinexus). We ensured that MEK1 protein levels were
similar in both samples, by performing a Western blot
analysis using ﬁrst an antibody against MEK1, and then,
on the same membrane, the p[Ser-297] antibody. Both
iRBC and uRBC extracts contained MEK1 protein;
indeed, MEK1 was more abundant in the uRBC extract.
However, the signal yielded by the p[Ser-297] antibody
was stronger in iRBCs than in uRBCs, despite a lower
amount of protein (Fig. 4B). This conﬁrms that MEK1 Ser-
297 phosphorylation is strongly stimulated in infected
erythrocytes. In contrast to the much stronger MEK1
p[Ser-297] signal in infected (versus uninfected) cells,
there was a decrease in the phosphorylation in iRBCs
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and Thr-385), as well as MEK2 Thr-394 (Fig. 4A). Phos-
phorylation of these three residues is involved in negative
feed-back loops (Brunet et al., 1994; Rossomando et al.,
1994; Xu et al., 1999; Sharma et al., 2002). This may be a
direct consequence of the overall lower level of MEK
protein in the iRBC extract; nevertheless, together with
the higher phosphorylation of Ser-297 which has a stimu-
latory effect on MEK1 activity (see below), this is consis-
tent with sustained activation of MEK1/2 in iRBCs. In
Fig. 1. Effect of MEK inhibitors on the P. falciparum erythrocytic asexual cycle.
A. Structure of the MEK inhibitors used in this study. The IC50 values on P. falciparum growth are indicated above the structures.
B. MEK inhibitors block trophozoite development. Synchronized cultures (2% parasitaemia) were treated at the ring stage with MEK inhibitors
(U0126 and PD184352, 20 mM), and aliquots were smeared at 0, 12, 30, 40 and 48 h post treatment. Cell numbers were obtained from
microscopic examination of 10 ﬁelds for each time point. The experiment was performed three times in triplicate, with similar results.
C. MEK inhibitors impair parasite DNA synthesis. Hypoxanthine incorporation along P. falciparum life cycle was measured in the presence of
MEK inhibitors (U0126 and PD184352, 20 mM). MEK inhibitors (or DMSO as a negative control) and [
3H]-hypoxanthine were added to tightly
synchronized cultures (3% parasitaemia, ring stage) at T0. The cells were then harvested at 8 h intervals, and precipitable tritium was
quantiﬁed by scintillation. Error bars show the SEM. The experiment was performed twice in triplicate, with similar results.
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are also present in the RBC proteome (Roux-Dalvai et al.,
2008), are not phosphorylated upon infection (Fig. S6).
Furthermore, we observed a slight phosphorylation of
MEK4 serine 80 in the infected erythrocytes, a phospho-
rylation known to lead to inactivation of the kinase
(Spillman et al., 2007). Thus, direct examination of the
phosphorylation status of MEK1 strongly supports the
pharmacological data implicating a pathway that selec-
tively involves MEK1 (versus MEK3 and MEK4) in infec-
tion of erythrocytes by malaria parasites.
Activation of a PAK1,MEK1 pathway in
infected erythrocytes
The only kinase known so far to phosphorylate MEK1 on
Ser-297 is the p21-activated protein kinase PAK, several
isoforms of which are present in mammalian cells (Slack-
Davis et al., 2003; Park et al., 2007). PAK isoforms have
also been shown to be represented in the RBC proteome
(Ringrose et al., 2008; Roux-Dalvai et al., 2008). In ﬁbro-
blasts, cell interaction with extracellular matrix triggers a
pathway leading to phosphorylation of MEK1 Ser-297 by
PAK1. This stimulates autophosphorylation of MEK1 on
the Ser-217/Ser-221 residues located in the activation
loop, leading to activation of the kinase (Park et al., 2007).
Thus, Ser-297 phosphorylation can be predicted to be
accompanied by phosphorylation of Ser-217/Ser-221 in
iRBCs. This indeed is what we observed by performing
Western blot analysis using a phospho-speciﬁc antibody
against MEK1 Ser-217/221 (which was not present on the
Kinexus KPSS7.0 panel) (Figs 4C and 5A). Furthermore,
and consistent with the proposition that phosphorylation
of Ser-297 lies upstream of Ser-217/Ser-221 autophos-
phorylation, treatment with U0126 or PD184352 strongly
decreased phosphorylation of Ser-217/221, but not of
Ser-297 (Fig. 4C).
The recently described IPA-3 molecule (Fig. 1A) is an
allosteric, highly selective inhibitor of PAK1, -2 and -3
(Deacon et al., 2008), which was shown to act by binding
covalently to the PAK regulatory domain and thereby
preventing binding to the upstream activator Cdc42
(Viaud and Peterson, 2009). If activation of host erythro-
cyte MEK1 is required for parasite survival, and if this
activation occurs via PAK-mediated phosphorylation
of MEK1 Ser-297, then we would predict PAK inhibition
to have similar parasiticidal effects as the MEK inhibitors.
We found that the IC50 of IPA-3 on parasite growth is
close to 2 mM (Fig. S1B). Since the compound has
only been identiﬁed recently, this value cannot be com-
pared with IC50 values in other cellular systems; however,
in the original report that ﬁrst describes the inhibitor,
Fig. 2. Effect of MEK inhibitors on P. berghei
erythrocytic and liver stages.
A. HepG2 cells were infected with P. berghei
expressing RFP under the control of the
promoter region of the constitutively
expressed P. berghei eukaryotic elongation
factor 1 alpha (eef1aa). Twenty-four hours
post infection, infected cell cultures were
treated with 25 mM UO126 for another 24 h or
were left untreated as a control. RFP
ﬂuorescence of parasites was monitored by
live imaging; the size of the parasite was
quantiﬁed and expressed in mm
2. Statistical
evaluation using the Student’s t-test revealed
a highly signiﬁcant difference in parasite size
(P: 0.0001).
B. Immediately after live imaging, cells were
ﬁxed and stained with an antiserum directed
against the PVM protein Exp1 (green). DNA
was visualized with DAPI (blue). Parasites
were still clearly visible by the remaining RFP
ﬂuorescence (red). Merged pictures are
presented on the right. Representative images
of treated (U0126) and untreated (DMSO)
cells are presented. This is one of several
similar pictures obtained with treated cells.
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A. Western blot of total-cell extracts from uRBCs after immunoprecipitation using either mouse anti-MEK1 agarose-conjugated or mouse IgG
agarose-conjugated as a control probed with an anti-MEK1 antibody.
B. Sequence Coverage of the identiﬁed MEK1 protein in erythrocyte.
C. Representative CID fragmentation pattern of a unique peptide identiﬁed in MEK1.
Fig. 4. Phosphorylation status of host cell
MEK1 in P. falciparum-infected erythrocytes.
A. Quantiﬁcation of Western blot data
obtained from Kinexus experiment (see text
for details and Fig. S5 for the original Western
blot). The autoradiogram was scanned to
obtain a counts per minute (c.p.m.) value
(scan time of 60 s). Data in Figs 4A and S5
were generated at Kinexus (Vancouver,
Canada) using cell extracts provided by the
authors.
B. Western blot of total-cell extracts from
uRBCs (lane 1) and iRBCs (lane 2). Lane 3
is a positive control extract (3T3 cells treated
with PDGF) provided by the supplier of the
antibodies (Biosource). The membrane was
probed ﬁrst with an anti-MEK1 antibody
recognizing both phosphorylated and
non-phosphorylated forms of the protein
(left panel). The same membrane was then
probed with the anti-phospho-MEK1 p[S297]
(right panel).
C. Effect of the PD184532 MEK inhibitor
on MEK phosphorylation. Synchronous
P. falciparum cultures were treated at ring
stage with 20 mM PD184532 (or with the
DMSO vehicle only) for 24 h prior to Western
blot analysis using the antibodies indicated to
the right.
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aimed at measuring cellular effects of IPA-3 (Deacon
et al., 2008). To verify that IPA-3 treatment did indeed
affect MEK1 phosphorylation, we performed a MEK1
p[Ser-297] Western blot analysis of extracts from IPA-3-
treated and untreated iRBCs. Treatment with IPA-3
clearly reduces phosphorylation of this MEK1 residue (by
two- to threefold as determined by autoradiogram scan-
ning), and as expected, also affects phosphorylation of
the serines in the activation loop (Fig. 5A). In other
systems, phosphorylation of PAK1 on Ser-144, which lies
in a kinase autoinhibitory domain, is known to signiﬁ-
cantly contribute to its activation (Chong et al., 2001). As
shown in Fig. 5B, Western blotting using a phospho-
speciﬁc antibody recognizing this residue gave a stronger
signal in iRBCs than in uRBCs, despite a lower amount of
PAK1 protein, similar to what we found for MEK1 (see
Fig. 4B). This demonstrates that PAK1, like MEK1, is acti-
vated in infected erythrocytes, and that MEK1 is activated
by PAK1 as a consequence of infection.
Pharmacological (using the IPA-3 inhibitor) and bio-
chemical (using an anti-p[Ser-144] antibody) data thus
concur to identify host erythrocyte PAK1 as being, like
MEK1, stimulated in infected (versus uninfected) RBCs.
Two pieces of evidence establish that both PAK1 and
MEK1 function in the same pathway: ﬁrst, the residue that
was found in the Kinexus screen to undergo the highest
level of phosphorylation in iRBCs is Ser-297 of MEK1; the
only kinase demonstrated so far to use this residue as a
substrate is PAK. Second, treatment of parasite cultures
with the PAK-speciﬁc inhibitor IPA-3 signiﬁcantly reduced
MEK1 Ser-297 phosphorylation.
Taken together, our pharmacological and biochemical
data strongly suggest that a PAK1→MEK1 pathway is
activated in malaria parasite-infected erythrocytes. This
raises exciting questions in two areas: ﬁrst, how does
parasite infection lead to activation of the host
PAK1→MEK1 pathway? One possibility is that PAK1 itself
may be the target of a parasite kinase. Alternatively,
hijacking of the pathway might occur upstream of PAK1. In
ﬁbroblasts, PAK1 is activated by interaction with GTP-
bound cdc42/Rac1 (Parrini et al., 2005), which in turn is
stimulated by adhesion of the cell to the extracellular
matrix (Park et al., 2007). That (i) the PAK inhibitor IPA-3
acts by preventing activation of the kinase through Cdc42
interaction and (ii) IPA-3 treatment reduces MEK1 Ser-
297 phosphorylation (Fig. 5A) points to a possible involve-
ment of Rac1/Cdc42 in the pathway. It is attractive to
speculate that the extensive remodelling of the erythro-
cyte plasma membrane following parasite infection may
trigger the Rac1/Cdc42→PAK1→MEK1 pathway as
described in ﬁbroblasts after interaction of the cell with the
extracellular matrix. It is noteworthy that MEK phosphory-
lation on S297 and on the activation loop is detectable
already at the ring stage (Fig. S7), when RBC remodelling
is initiated. Second, why is host MEK1 activity required for
parasite survival? Erythrocyte MAPK pathways having
been implicated in the regulation of transporters (Sartori
et al., 1999), it may be that MEK1 participates in the
activation of the ‘novel permeation pathway’ that permits
import of nutrients into the iRBC. Indeed, NPP activation
was shown to be susceptible to kinase inhibitors
(Baumeister et al., 2006). There are a number of other
possible effectors of the pathway; identifying substrates of
MEK1 in iRBC will be crucial in understanding the essen-
tial role this kinase plays in parasite survival. Data in
Fig. 4A suggest that infection also affects MEK2; the MEK
inhibitors used in our study are effective against both
MEK1 and MEK2, and also inhibit MEK5 (Squires et al.,
2002; Bain et al., 2007). It follows that the parasiticidal
effect of these molecules may be mediated by several
parallel host cell MAPK pathways. We were surprised
not to observe a signiﬁcant phosphorylation of ERK1/2
in iRBCs (data not shown), as these MAPKs are the
Fig. 5. Effects of PAK1 inhibitors on MEK1 phosphorylation and phosphorylation status of host erythrocyte PAK1 in P. falciparum-infected
cells.
A. Effect of the IPA-3 PAK1 inhibitor on MEK1 Ser-297 phosphorylation. Synchronous P. falciparum cultures were treated at ring stage with
15 mM IPA-3 (or with the DMSO vehicle only) for 27 h prior to Western blot analysis using the antibodies indicated to the right. URBC,
uninfected red blood cells.
B. Increased phosphorylation of PAK1 Ser-144 in iRBCs. A Western blot analysis was performed on protein extracts from in vitro cultured
infected (I) or uninfected (U) RBC ghosts using anti-PAK1 antibody (Cell Signaling; top panel) or anti-phospho-PAK 1/2/3 (Ser-144) (Invitrogen;
bottom panel). Lane C (positive control) contains an extract of A673 cells (Santa Cruz).
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MEK is diverted to non-conventional substrates in this
case.
Even though our data fully support modulation of the
host PAK1→MEK1 pathway following infection, we cannot
exclude that unidentiﬁed parasite-encoded targets con-
tribute to the parasiticidal effect of the inhibitors. However,
we checked that U0126 has no detectable effect on the
in vitro activity of the three P. falciparum protein kinases
for which weak similarity with mammalian MEKs has been
documented: PfPK7 (PlasmoDB identiﬁer PFB0605w), a
‘composite kinase’ whose C-terminal lobe shows maximal
homology to MEK3/6 [but whose N-terminal lobe is most
similar to fungal PKAs (Dorin et al., 2005) and which is not
essential for survival of asexual blood-stage parasites
(Dorin-Semblat et al., 2008)]; Pfnek-1 (PlasmoDB identi-
ﬁer PFL1370w), which, despite an overall high similarity to
NIMA kinases, possesses a MEK1-like activation loop
(Dorin et al., 2001); and PfPK8 (PlasmoDB identiﬁer
PFB0150c), for which a distant relation to some STE
kinases (the group of kinases that includes MEKs) has
been proposed (Anamika et al., 2005) (data not shown).
Taken together, the clear evidence provided here that
host RBC MEK1 undergoes activating phosphorylation
events upon infection, and the high selectivity of the PAK
and MEK inhibitors used in this study, strongly point to a
crucial role of a host cell PAK-MEK pathway in parasite
survival.
Impact on antimalarial drug discovery
The ﬁnding that allosteric MEK and PAK inhibitors have
parasiticidal activity has considerable implications in strat-
egies for antimalarial drug discovery. Several protein
kinase inhibitors have reached the market, mostly as anti-
cancer agents, in the recent years (Zhang et al., 2009),
and MAPK pathway components (notably MEKs) are con-
sidered as attractive targets for cancer chemotherapy
(Sebolt-Leopold and Herrera, 2004). It will be important to
verify whether the MEK inhibitors discussed here have a
‘cidal’ or a ‘static’ effect on the parasite; nevertheless, in
more general terms, we propose that inhibitors of human
kinases (MEK or others) that successfully pass Phase 1
and/or Phase 2 clinical trials, but pass or fail Phase 3 for
their original target disease, are evaluated for antimalarial
properties. This would considerably reduce the overall
discovery/development costs of antimalarials and accel-
erate the process. A potential problem associated with
targeting human enzymes is the toxicity of the com-
pounds; however, this has not prevented the registration
of kinase inhibitors for cancer treatment, even though
anticancer agents must generally be administered for
extended periods of time. In contrast, treatment of severe
malaria requires only short treatment periods, limiting the
toxicity problem. Importantly, targeting a human enzyme
would deprive the parasite of the most straightforward
mechanism for emergence of drug resistance, namely the
selection of genotypes expressing a mutated, resistant
target. That both P. falciparum and P. berghei are suscep-
tible to MEK inhibitors indicates that reliance on host RBC
signalling pathways is widespread across the genus Plas-
modium, and suggests that other species infecting
humans (e.g. Plasmodium vivax, which, like P. berghei,
infects preferentially reticulocytes) are likely to share this
feature. Our ﬁndings thus deﬁne a novel paradigm for
strategies towards the discovery and development of anti-
malarials with a novel mode of action.
Experimental procedures
P. falciparum culture and hypoxanthine
incorporation assay
Plasmodium falciparum (clone 3D7) was grown in human eryth-
rocytes as described previously (Dorin et al., 1999). U0126 and
PD98059 were supplied by Calbiochem. PD184352 was either
provided by Prof. Philip Cohen (MRC Protein Phosphorylation
Unit, University of Dundee, UK), or synthesized by JAS (see
Supporting information). IPA-3 was provided by Jeffrey Peterson
(Fox Chase Cancer Center, Philadelphia, USA). Inhibitors were
dissolved in DMSO, and IC50 values were determined by the
[
3H]-hypoxanthine incorporation assay (Desjardins et al., 1979).
Brieﬂy, asynchronous parasites were aliquoted in 96-well plate at
a 0.5% parasitaemia and 5% haematocrit in the presence of the
inhibitor (0.04–100 mM). [
3H]-hypoxanthine (0.1 mCi per well) was
added after 24 h and the cells were harvested on a ﬁlter mat after
a further 24 h of culture. Scintillation liquid was added onto the
ﬁlter mat and radioactivity counted using a b-scintillation counter.
All assays were carried out using untreated parasites with DMSO
as controls. Assays were run at least twice in triplicates.
Soluble protein extracts and Western blots
To obtain infected cell pellets free of uRBCs, asynchronous cul-
tures were passed through a magnetic column (MACS) (130-041-
305/MiltenyiBiotec) that retain trophozoite- and schizont-infected
cells, but not younger stages or uRBCs. uRBCs and MACS-
puriﬁed iRBCs were counted on haematimeter, and the same
number of cells were sonicated in a lysis buffer containing phos-
phatase and protease inhibitors (20 mM Tris pH 7.5, 2 mM EGTA,
5 mM EDTA, 30 mM NaF, 40 mM b-glycerophosphate, 20 mM
sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM
PMSF, 3 mM benzamidine, 5 mM pepstatin A, 10 mM leupeptin
and 0.5% Triton X-100). Lysates were cleared by centrifugation at
10 000 g for 15 min at 4°C.
For Western blot analysis, iRBC and uRBC samples were
normalized by cell number. Polyacrylamide gel electrophoresis
(SDS-PAGE) and transfer were performed using standard proce-
dure. The nitrocellulose membrane was blocked for 1 h in Tris-
buffered saline (pH 7.6) (TBS) containing 0.1% Tween-20 with
5% w/v non-fat dry milk and exposed overnight at 4°C to the
primary antibody [1:1000 dilution in blocking buffer for anti-MEK1
842 A. Sicard et al.
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pho-speciﬁc antibodies: anti-p[S217–S221] from Calbiochem,
anti-p[S217–S221] from Santa Cruz and anti-p[S297] from Bio-
Source]. After washing, the membrane was incubated for 1 h at
room temperature with 1:1000 anti-rabbit horseradish
peroxidase-conjugated secondary antibody (Sigma). Detection
was performed using the ECL Chemiluminescence system from
Perkin-Elmer following the manufacturer’s recommendations.
For experiments performed at Kinexus, extracts were prepared
according to Kinexus recommendations and shipped on dry ice.
Protein extraction and mass spectrometry analysis
Uninfected erythrocytes were lysed with 150 mM NaCl, 5 mM
EDTA, 50 mM Tris pH 8.0, 1% Triton X-100 and centrifuged at
13 000 r.p.m. for 20 min at 4°C. The supernatant was used for
immunoprecipitation using either mouse anti-MEK1 agarose-
conjugated (Santa-Cruz Biotechnology) or mouse IgG agarose-
conjugated (Santa Cruz) as a control for 4 h on a wheel at 4°C.
Beads were washed four times with PBS mixed with 4¥ Laemelli
and boil before electrophoresis of duplicate gels. One gel was
Coomassie stained while the other was blotted onto a nitrocellu-
lose membrane. The presence of MEK1 was detected as
described previously. Spots corresponding to immunoreactive
regions of the blot were excised from the Coomassie-stained gel
(Fig. S4A). After in-gel digestion, tryptic peptides were separated
by nanoﬂowrpHPLC and analysed on an LTQ-Orbitrap XL mass
spectrometer (Thermo Fisher Scientiﬁc). Data search was per-
formed using Mascot 2.2 (Matrix Science) in Proteome Discov-
erer v.1.1 against a concatenated database consisting of the
Swiss-Prot v.57.13 database and the reversed-sequence version
of the same database. Data were visualized using Scaffold 3
software.
Preparation of ghosts and protein extraction
Proteins of ghosts from uninfected and infected erythrocytes
were extracted according to Blisnick et al. (2000). Uninfected
erythrocytes and infected erythrocytes were incubated 30 min at
4°C in 1:10 and 1:5, respectively, diluted RPMI and spun 45 min
at 5100 r.p.m. at 4°C. The upper layer containing the haemoglo-
bin was discarded. The bottom layer was washed three times
3 min in lysis buffer at 13 000 r.p.m. at 4°C. Proteins were
extracted using 50 mM Tris pH 8.0, 300 mM NaCl, 0.1 mM EDTA,
1% Triton X-100 supplemented with proteases and phos-
phatases inhibitors and subjected to Western blot analysis as
described above.
Determination of IC50 values on P. berghei blood-stage
proliferation
In vitro drug susceptibility test was performed in standard short-
term cultures of synchronized P. berghei blood stages. See
Supporting information for details.
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Fig. S1. Effect of allosteric inhibitors of host erythrocyte kinases
on P. falciparum proliferation. The [3H]-hypoxanthine
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© 2011 Blackwell Publishing Ltd, Cellular Microbiology, 13, 836–845incorporation was used (see Experimental procedures for
details). Assays were run twice in triplicates and error bars cor-
respond to SEM.
A. MEK inhibitors. The range of the concentrations used was
0.412–100 mM for U0126 and PD98059, and 0.041–20 mMf o r
PD184352.
B. PAK inhibitor IPA-3.
Fig. S2. MEK inhibitors do not affect egress or invasion.
Schizont-enriched cultures (0.5% parasitaemia) were treated
with MEK inhibitors (U0126 and PD184352, 20 mM) or the vehicle
(DMSO) as negative control.Aliquots were smeared at the time of
treatment (labelled ‘T0’, left) and 12 h post treatment (‘T12’,
right), and the parasitaemia examined. Cell numbers were
obtained from microscopic examination of 10 ﬁelds for each time
point. For each condition, assays were performed in triplicates.
The treatment did not decrease the number and proportion of
rings following re-invasion.
Fig. S3. Determination of the IC50 values of MEK inhibitors on P.
berghei blood-stage proliferation. In vitro drug susceptibility test
was performed in standard short-term cultures of synchronized P.
berghei blood stages. Cultured and puriﬁed schizonts/
merozoites, obtained by Nycodenz density gradient puriﬁcation
were injected i.v. into the tail vein of a rat. Injected merozoites
invade within 4 h after injection and newly infected blood
was collected from the rat by heart puncture at 4 h after the
injection of the puriﬁed schizonts/merozoites. Infected blood was
washed once (450 g, 8 min) with complete culture medium
(RPMI + 25% FCS) followed by mixing of infected erythrocytes
with serial solutions of the drugs in complete culture medium and
incubated in 24-well plates in triplicate at a ﬁnal concentration of
1% at 35°C for 24 h thus allowing the ring forms/young tropho-
zoites to develop into mature schizonts. Parasite development
was analysed by FACS analysis after staining of the parasites
with the DNA-speciﬁc dye Hoechst33258. The cell suspension
(0.5 ml) of each well was transferred to an Eppendorf tube and
cells were pelleted by centrifugation (13 000 g for 5 s). After
removal of the culture medium, the cells were ﬁxed in 500 mlo fa
0.25% glutaraldehyde/PBS solution and stored at 4°C until stain-
ing. Prior to ﬂow-cytometric analysis, the cells were stained in
500 mlo fa2mM Hoechst33258 solution in PBS for 1 h at 37°C.
Stained cells were analysed using a MACSQuant analyser (Milte-
nyi Biotec, Germany). UV excitation of Hoechst33258 dye was
performed with a violet laser (450/50 nm) and the (infected)
erythrocyte population was selected by gating on forward/
sidelight scatter. The ﬂuorescence intensity of a total of 50 000
cells per sample was measured for each sample. The mean
ﬂuorescence intensity of the infected erythrocyte population,
which is proportional to the mean DNA content of the parasites,
was calculated for each drug concentration in triplicate. For cal-
culation of the growth inhibitory curves, the mean ﬂuorescence
intensity value of samples with the highest drug concentration
(i.e. with maximum inhibition of growth) was subtracted from the
mean ﬂuorescence intensity value of the samples with the other
drug concentrations and the control samples without drug. The
mean ﬂuorescence intensity value of the control samples was set
at 100% and the mean ﬂuorescence value of the highest drug
concentration was set at 0% for calculation of the percentage of
inhibition. Growth inhibitory curves were constructed in MS Excel.
Fig. S4. Immunoprecipitation and mass spectrometry analysis of
erythrocytic MEK1.
A. Coomassie-stained gel of total-cell extracts from uRBCs after
immunoprecipitation using either mouse anti-MEK1 agarose-
conjugated (lane 1) or mouse IgG agarose-conjugated as a
control (lane 2).
B. List of the 24 unique peptides leading to the identiﬁcation of
MEK1 following mass spectrometry analysis.
Fig. S5. Western blot of total-cell extracts from uRBCs (lane 1)
and iRBCs (lane 2) probed with an anti-phospho-MEK1 p[S297]
antibody. This experiment was performed at Kinexus.
Fig. S6. Phosphorylation status of host cell MEK1, MEK3 and
MEK4 in P. falciparum-infected erythrocytes. Quantiﬁcation of the
signal of MEK1 S297, MEK3 S189, MEK4 S257 + T261 and
MEK4 S80 in uninfected erythrocytes (white columns) and
infected erythrocytes (black columns) from a second Kinexus
experiment.
Fig. S7. Western blot of protein extracts from in vitro cultured
infected RBCs ghosts at rings, trophozoites and schizonts stages
(as determined by Giemsa staining) probed with the antibodies
indicated to the right.
Please note: Wiley-Blackwell are not responsible for the content
or functionality of any supporting materials supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
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